Skip to content
10-Q

Quarterly Report

Voyager Therapeutics, Inc. VYGR

0001558370-25-006484

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 55.34M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $74.76M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $71.37M
Current Liabilities Q1 2025 · Mar 31, 2025 $40.21M
Current Liabilities Q1 2025 · Dec 31, 2024 $49.79M
Total Liabilities Q1 2025 · Mar 31, 2025 $80.54M
Total Liabilities Q1 2025 · Dec 31, 2024 $93.29M
Current Assets Q1 2025 · Mar 31, 2025 $245.21M
Current Assets Q1 2025 · Dec 31, 2024 $276.81M
Total Assets Q1 2025 · Mar 31, 2025 $353.24M
Total Assets Q1 2025 · Dec 31, 2024 $393.05M
Shares Diluted Q1 2025 · Mar 31, 2024 57.12M sh
Capex Q1 2025 · Mar 31, 2024 $2.14M
Operating Cash Flow Q1 2025 · Mar 31, 2024 $58.77M
Stockholders Equity Q1 2025 · Mar 31, 2024 $340.89M
Stockholders Equity Q1 2025 · Dec 31, 2023 $236.32M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.20
Eps Basic Q1 2025 · Mar 31, 2024 −$0.20
Sga Expense Q1 2025 · Mar 31, 2024 $8.61M
Rd Expense Q1 2025 · Mar 31, 2024 $27.09M
Net Income Q1 2025 · Mar 31, 2024 −$11.33M
Operating Income Q1 2025 · Mar 31, 2024 −$16.18M
Revenue Q1 2025 · Mar 31, 2024 $19.52M